Table 3.

Prognostic impact of the new BCP-ALL risk stratification model proposed for DFS of patients included in the childhood BCP-ALL validation cohort, the childhood BCP-ALL discovery + validation cohorts, and the adult BCP-ALL validation cohort.

	Univariate Analysis				Multivariate Analysis
	Median DFS (Years)	HR	95th CI	p-Value	HR	95th CI	p-Value
CHILDHOOD BCP-ALL
Validation Cohort
MRD Status         Day +78    MRD−	6.43	1
MRD+	3.49	8.25	(2.20–30.84)	0.002
%Endothelial cells (EC)    Day +78    ≤32%	6.35	1
>32%	4.16	4.52	(1.13–18.10)	0.033
Day +78 MRD Status and % EC
MRD− and %EC ≤ 32%	6.50	1		0.001	1		0.001
MRD+ or %EC ≤ 32% MRD−or %EC > 32%	3.94	6.35	(1.42–28.50)		6.35	(1.42–28.50)
MRD+ and %EC > 32%	3.54	9.81	(1.79–53.88)		9.81	(1.79–53.88)
Discovery plus Validation Cohort
MRD Status         Day +33    MRD−	6.30	1
MRD+	5.74	2.64	(1.14–6.08)	0.023
Day +78    MRD−	6.24	1
MRD+	3.30	4.34	(1.96–9.63)	<0.001
% Stromal cell at       Day +33   ≤0.21%	6.25	1
>0.21%	4.55	3.17	(1.47–6.85)	0.003
% Endothelial cells (EC) Day +78       ≤32%	6.28	1
>32%	4.00	2.88	(1.43–5.80)	0.003
Day +78 MRD Status and % EC
MRD− and %EC ≤ 32%	6.38	1			1
MRD+ or %EC ≤ 32% MRD− or %EC > 32%	4.13	2.92	(1.41–6.03)	<0.001	2.92	(1.41–6.03)	<0.001
MRD+ and %EC > 32%	2.60	8.03	(2.69–24.02)		8.03	(2.69–24.02)
ADULT BCP-ALL
Validation Cohort
MRD Status         Day +33   MRD−	3.87	1
MRD+	1.80	3.40	(1.41–8.18)	0.006
Day +78    MRD−	3.64	1
MRD+	1.94	3.26	(1.28–8.32)	0.014
Day +78 MRD Status and % EC
MRD− and %EC ≤ 32%	3.64	1		0.004	1		0.004
MRD+ or %EC ≤ 32% MRD− or %EC > 32%	2.52	2.99	(0.80–6.63)		2.99	(0.80–6.63)
MRD+ and %EC > 32%	0.92	8.33	(2.08–33.40)		8.33	(2.08–33.40)

Abbreviations: CI: confidence interval; HR: hazard ratio; MRD: minimal residual disease; EC: endothelial cell.